A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 2, 2015, Pages 301-311

  Kim, Sang Soo ^a   Rait, Antonina ^a   Kim, Eric ^b   Pirollo, Kathleen F ^a   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b SynerGene Therapeutics Inc   (United States)

Author keywords

Chemosensitization; Glioblastoma multiforme; Limiting TMZ resistance; P53; Systemic nanodelivery; Temozolomide

Indexed keywords

CELL CULTURE; CELL DEATH; TUMORS;

BLOOD-BRAIN BARRIER; CHEMO SENSITIZATIONS; EFFECTIVE THERAPY; GLIOBLASTOMA MULTIFORME; NANO-DELIVERY SYSTEMS; SYSTEMIC NANODELIVERY; TEMOZOLOMIDE; TUMOR SUPPRESSOR GENES;

DIAGNOSIS;

NANOCARRIER; PROTEIN P53; SGT 53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; DACARBAZINE; NANOPARTICLE; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SURVIVAL RATE; SURVIVAL TIME; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD BRAIN BARRIER; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE TRANSFER; GENETICS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BLOOD-BRAIN BARRIER; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE TRANSFER TECHNIQUES; GLIOBLASTOMA; HUMANS; MICE; NANOPARTICLES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922777150     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.09.005     Document Type: Article

References (41)

1. Nagasawa D.T., Chow F., Yew A., Kim W., Cremer N., Yang I. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 2012, 23(2):307-322.
2. Vredenburgh J.J., Desjardins A., Herndon J.E., Dowell J.M., Reardon D.A., Quinn J.A., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4):1253-1259.
3. Hou L.C., Veeravagu A., Hsu A.R., Tse V.C. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 2006, 20(4):E5.
4. Chamberlain M.C. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 2010, 10(10):1537-1544.
5. Sun S., Lee D., Ho A.S., Pu J.K., Zhang X.Q., Lee N.P., et al. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol 2013, 15(5):562-577.
6. Ma J., Murphy M., O'Dwyer P.J., Berman E., Reed K., Gallo J.M. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol 2002, 63(7):1219-1228.
7. Fruehauf J.P., Brem H., Brem S., Sloan A., Barger G., Huang W., et al. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 2006, 12(15):4523-4532.
8. Bocangel D., Sengupta S., Mitra S., Bhakat K.K. p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res 2009, 29(10):3741-3750.
9. Quinn J.A., Desjardins A., Weingart J., Brem H., Dolan M.E., Delaney S.M., et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005, 23(28):7178-7187.
10. Liu L., Gerson S.L. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006, 12(2):328-331.
11. Natsume A., Ishii D., Wakabayashi T., Tsuno T., Hatano H., Mizuno M., et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 2005, 65(17):7573-7579.
12. Natsume A., Wakabayashi T., Ishii D., Maruta H., Fujii M., Shimato S., et al. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol 2008, 61(4):653-659.
13. Yoshino A., Ogino A., Yachi K., Ohta T., Fukushima T., Watanabe T., et al. Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Int J Oncol 2009, 35(1):139-148.
14. Kohsaka S., Wang L., Yachi K., Mahabir R., Narita T., Itoh T., et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther 2012, 11(6):1289-1299.
15. Bobustuc G.C., Baker C.H., Limaye A., Jenkins W.D., Pearl G., Avgeropoulos N.G., et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 2010, 12(9):917-927.
16. Hirose Y., Berger M.S., Pieper R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001, 61(5):1957-1963.
17. Kim S.S., Rait A., Kim E., Pirollo K.F., Nishida M., Farkas N., et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano 2014, 8(6):5494-5514.
18. Biddlestone-Thorpe L., Sajjad M., Rosenberg E., Beckta J.M., Valerie N.C., Tokarz M., et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res 2013, 19(12):3189-3200.
19. Shchors K., Persson A.I., Rostker F., Tihan T., Lyubynska N., Li N., et al. Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci U S A 2013, 110(16):E1480-E1489.
20. Steele R.J., Lane D.P. P53 in cancer: a paradigm for modern management of cancer. Surgeon 2005, 3(3):197-205.
21. Xu L., Pirollo K.F., Tang W.H., Rait A., Chang E.H. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999, 10(18):2941-2952.
22. Xu L., Tang W.H., Huang C.C., Alexander W., Xiang L.M., Pirollo K.F., et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 2001, 7(10):723-734.
23. Xu L., Huang C.C., Huang W., Tang W.H., Rait A., Yin Y.Z., et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 2002, 1(5):337-346.
24. Pirollo K.F., Rait A., Zhou Q., Zhang X.Q., Zhou J., Kim C.S., et al. Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin Cancer Res 2008, 14(7):2190-2198.
25. Yu W., Pirollo K.F., Yu B., Rait A., Xiang L., Huang W., et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 2004, 32(5):e48.
26. Xu L., Frederik P., Pirollo K.F., Tang W.H., Rait A., Xiang L.M., et al. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther 2002, 13(3):469-481.
27. Pirollo K.F., Zon G., Rait A., Zhou Q., Yu W., Hogrefe R., et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006, 17(1):117-124.
28. Pirollo K.F., Rait A., Zhou Q., Hwang S.H., Dagata J.A., Zon G., et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007, 67(7):2938-2943.
29. Hwang S.H., Rait A., Pirollo K.F., Zhou Q., Yenugonda V.M., Chinigo G.M., et al. Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol Cancer Ther 2008, 7(3):559-568.
30. Kim S.S., Rait A., Rubab F., Rao A.K., Kiritsy M.C., Pirollo K.F., et al. The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Mol Ther 2014, 22(2):278-291.
31. Nathanson D., Mischel P.S. Charting the course across the blood-brain barrier. J Clin Invest 2011, 121(1):31-33.
32. Camp E.R., Wang C., Little E.C., Watson P.M., Pirollo K.F., Rait A., et al. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther 2013, 20(4):222-228.
33. Pirollo K.F., Hao Z., Rait A., Jang Y.J., Fee W.E., Ryan P., et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997, 14(14):1735-1746.
34. Senzer N., Nemunaitis J., Nemunaitis D., Bedell C., Edelman G., Barve M., et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther 2013, 21(5):1096-1103.
35. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
36. Moen E.L., Stark A.L., Zhang W., Dolan M.E., Godley L.A. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide. Mol Cancer Ther 2014, 13(5):1334-1344.
37. Clarke M.J., Mulligan E.A., Grogan P.T., Mladek A.C., Carlson B.L., Schroeder M.A., et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 2009, 8(2):407-414.
38. Kohsaka S., Tanaka S. Chemotherapeutic agent for glioma. Clinical management and evolving novel therapeutic strategies for patients with brain tumors 2013, 415-438. InTech, Rijeka, Croatia. T. Lichtor (Ed.).
39. Lin J., Tang H., Jin X., Jia G., Hsieh J.T. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene 2002, 21(19):3082-3088.
40. Lant B., Storey K.B. An overview of stress response and hypometabolic strategies in Caenorhabditis elegans: conserved and contrasting signals with the mammalian system. Int J Biol Sci 2010, 6(1):9-50.
41. Roos W.P., Batista L.F., Naumann S.C., Wick W., Weller M., Menck C.F., et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007, 26(2):186-197.